BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23403462)

  • 1. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
    Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
    Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heritable genetic background alters survival and phenotype of Mll-AF9-induced leukemias.
    Young K; Loberg MA; Eudy E; Schwartz LS; Mujica KD; Trowbridge JJ
    Exp Hematol; 2020 Sep; 89():61-67.e3. PubMed ID: 32768438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape.
    Chiarella E; Aloisio A; Scicchitano S; Todoerti K; Cosentino EG; Lico D; Neri A; Amodio N; Bond HM; Mesuraca M
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
    Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
    Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment?
    Muntean AG; Hess JL
    Cancer Cell; 2008 Jun; 13(6):465-7. PubMed ID: 18538728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia.
    Zhang Y; Owens K; Hatem L; Glass CH; Karuppaiah K; Camargo F; Perkins AS
    Blood; 2013 Oct; 122(16):2888-92. PubMed ID: 24021671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
    Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
    Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.
    Wei J; Wunderlich M; Fox C; Alvarez S; Cigudosa JC; Wilhelm JS; Zheng Y; Cancelas JA; Gu Y; Jansen M; Dimartino JF; Mulloy JC
    Cancer Cell; 2008 Jun; 13(6):483-95. PubMed ID: 18538732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of the Shb gene in mixed-lineage leukemia MLL-AF9 cells increases latency in mice despite higher proliferation rates in vitro.
    Jamalpour M; Bergquist E; Welsh M
    Exp Cell Res; 2020 Dec; 397(2):112368. PubMed ID: 33220260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Learning from mouse models of MLL fusion gene-driven acute leukemia.
    Schwaller J
    Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
    Chen Y; Ernst P
    Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.
    Armenteros-Monterroso E; Zhao L; Gasparoli L; Brooks T; Pearce K; Mansour MR; Martens JHA; de Boer J; Williams O
    Leukemia; 2019 Dec; 33(12):2817-2829. PubMed ID: 31138842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
    Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
    Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ets1 Plays a Critical Role in MLL/EB1-Mediated Leukemic Transformation in a Mouse Bone Marrow Transplantation Model.
    Fu JF; Yen TH; Huang YJ; Shih LY
    Neoplasia; 2019 May; 21(5):469-481. PubMed ID: 30974389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
    Nguyen AT; Taranova O; He J; Zhang Y
    Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
    Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
    Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
    Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
    Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
    Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
    J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.
    Jenkins CE; Shevchuk OO; Giambra V; Lam SH; Carboni JM; Gottardis MM; Holzenberger M; Pollak M; Humphries RK; Weng AP
    Exp Hematol; 2012 Sep; 40(9):715-723.e6. PubMed ID: 22613471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.